Fig. 5: Prophylactic treatment against SARS-CoV-2 infection in Syrian hamsters. | Communications Biology

Fig. 5: Prophylactic treatment against SARS-CoV-2 infection in Syrian hamsters.

From: From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis

Fig. 5

a Dosing regimen. Syrian hamsters (n = 6, per group) pre-treated with a non-targeting siRNA (negative control, grey), the LY-CoV555 antibody (positive control, yellow) or our lead siRNA cocktail (treatment, red) were infected with 4 × 103 PFUs of the ancestral SARS-CoV-2 strain; b Weight change post infection. Box plot of the change in weight by treatment group relative to time postinfection; c, d Viral load at day 5 postinfection. All measurements were based on qPCR of the RdRP gene five days postinfection from homogenised lungs c and nares d. In all panels p value is presented as: *<0.05,**<0.001. Ctrl: control; VL: viral load; Neg.: negative; Pos.: positive; tment: treatment; n.s.: not significant. In panels b–d, horizontal lines represent the median, box edges represent the 25% and 75% quartiles, and the whiskers represent the furthest data points within up to 50% of the interquartile range. P-values were computed using parametric bootstrap (Methods).

Back to article page